Man Group
BDTX icon

Man Group’s Black Diamond Therapeutics BDTX Stock Holding History

Man Group’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-559,700
Closed -$1.19M – 2345
2026
Q1 		$1.19M Buy
559,700
+429,667
+330% +$1.02M ﹤0.01% 1771
2025
Q4 		$316K Buy
130,033
+51,707
+66% +$183K ﹤0.01% 2005
2025
Q3 		$297K Buy
78,326
+36,749
+88% +$107K ﹤0.01% 2007
2025
Q2 		$103K Buy
+41,577
New +$80.1K ﹤0.01% 2118
2024
Q3 		– Sell
-12,416
Closed -$57.9K – 1970
2024
Q2 		$57.9K Sell
12,416
-107,044
-90% -$575K ﹤0.01% 1981
2024
Q1 		$606K Buy
+119,460
New +$482K ﹤0.01% 1723

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Man Group's BDTX Position: Q2 2026 in Review

Man Group sold out of Black Diamond Therapeutics (BDTX) in Q2 2026, closing a stake of 559,700 shares — an estimated $1.19M sold.

Man Group first reported a position in BDTX in Q1 2024 and held it in 6 quarters. The position peaked at $1.19M in Q1 2026. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Man Group reported no remaining Black Diamond Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Man Group sold 559,700 Black Diamond Therapeutics shares in Q2 2026, an estimated $1.19M.
  • Man Group first reported a position in Black Diamond Therapeutics in Q1 2024 and held it in 6 quarters.
  • Man Group's Black Diamond Therapeutics position peaked at $1.19M in Q1 2026.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.